Background: Epigallocatechin-3-gallate (EGCG) is an important pharmacological
component in tea, and various effects, including anti-tumor, anti-inflammation, anti-aging, antiobesity,
anti-diabetes, cardiovascular disease prevention and protection, immunoregulation, and
neuroprotection, of this component have been confirmed. However, EGCG has been rarely used in
clinical applications because of its poor stability and low bioavailability.
Objective: The work summarizes the characteristics about EGCG, describes its pharmacological
mechanisms, explores the clinical availability of EGCG, and establishes a basis for EGCG
preparations in clinical applications.
Conclusion: In addition to altering dosage forms or synthesizing analogs to overcome losses during
absorption, inducing gauxiliary effect and enhancing chemosensitivity can be achieved by EGCG in
a combined medication. The pharmacological action, pharmacology network, including mutation of
signaling receptor and modulation of intracellular signaling pathway, and combination treatment
strategy of EGCG are clarified and distinguished. Possible targets and combined applications based
on the characteristics of EGCG are also systematically summarized. EGCG may be a candidate
compound that maintains balance of the patient's disease progression and becomes suitable for
clinical use in combination treatment.